D. E. Shaw & Co. Inc. Has $3.15 Million Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

D. E. Shaw & Co. Inc. boosted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 83.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 133,772 shares of the company's stock after acquiring an additional 60,732 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.13% of Dyne Therapeutics worth $3,152,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. abrdn plc purchased a new stake in Dyne Therapeutics in the 4th quarter valued at approximately $608,000. Raymond James Financial Inc. acquired a new position in Dyne Therapeutics during the fourth quarter worth $2,340,000. Barclays PLC raised its position in Dyne Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 207,309 shares of the company's stock worth $7,446,000 after acquiring an additional 128,246 shares in the last quarter. Schroder Investment Management Group lifted its holdings in Dyne Therapeutics by 63.3% in the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock valued at $3,477,000 after acquiring an additional 56,961 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Dyne Therapeutics by 54.5% during the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock worth $913,000 after purchasing an additional 13,677 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DYN. Scotiabank began coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price on the stock. BMO Capital Markets assumed coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price target for the company. JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. Piper Sandler lowered their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $47.25.

Dyne Therapeutics Trading Down 1.8%

NASDAQ:DYN traded down $0.21 during trading hours on Friday, hitting $11.69. The stock had a trading volume of 1,469,291 shares, compared to its average volume of 1,640,279. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45. The business has a 50 day simple moving average of $10.32 and a two-hundred day simple moving average of $16.83. The company has a market cap of $1.33 billion, a PE ratio of -3.28 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.